INTRADUCTAL PAPILLARY-MUCINOUS CARCINOMA OF PANCREAS

This adverse event was reported 65 times

These drugs are most commonly taken by patients reporting INTRADUCTAL PAPILLARY-MUCINOUS CARCINOMA OF PANCREAS:

# Drug Count
0 SITAGLIPTIN 6
1 ADALIMUMAB 5
2 AZATHIOPRINE 5
3 EXENATIDE 5
4 LIRAGLUTIDE 5
5 METFORMIN 5
6 METFORMIN ER 500 MG 5
7 METFORMIN ER 750 MG 5
8 PREDNISOLONE 5
9 PREDNISOLONE ORAL 5
See all common drugs associated with INTRADUCTAL PAPILLARY-MUCINOUS CARCINOMA OF PANCREAS

INTRADUCTAL PAPILLARY-MUCINOUS CARCINOMA OF PANCREAS is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 NIRAPARIB TOSYLATE MONOHYDRATE AND ABIRATERONE ACETATE 1 0.0161
1 ZAFIRLUKAST 1 0.0011
2 METRELEPTIN 1 0.0008
3 FLURBIPROFEN 1 0.0007
4 SILODOSIN 1 0.0002
5 DICLOFENAC EPOLAMINE 1 0.0002
6 SITAGLIPTIN AND METFORMIN HYDROCHLORIDE 4 0.0002
7 ETODOLAC 1 0.0002
8 NABUMETONE 1 0.0002
9 DICLOFENAC SODIUM AND MISOPROSTOL 1 0.0002
See all drugs enriched for association with INTRADUCTAL PAPILLARY-MUCINOUS CARCINOMA OF PANCREAS